MorphoSys’s worldwide partnering track record spans a wide range of agreements, from collaborations with academia and innovative biopharmaceutical start-ups to drug discovery alliances with several of the largest pharmaceutical companies like Novartis, Roche, Johnson & Johnson/Janssen, Pfizer, Bayer and Boehringer Ingelheim. For the further development and commercialization of our proprietary clinical-stage programs we have been able to attract GlaxoSmithKline. These productive partnerships have resulted in one of the largest therapeutic antibody pipelines to date.
MorphoSys is dedicated to becoming a fully integrated biopharmaceutical company including late-stage clinical development and marketing/co-promotion of its own drugs. With our goal of engineering the medicines of tomorrow in mind, we are always interested in new collaborations with innovative, science-driven organizations and academic institutions.